Close
Help





JOURNAL

Breast Cancer: Basic and Clinical Research

Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer

Submit a Paper


Breast Cancer: Basic and Clinical Research 2016:10 239-252

Review

Published on 04 Jan 2017

DOI: 10.4137/BCBCR.S12443


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Breast Cancer: Basic and Clinical Research

Abstract

Everolimus combined with exemestane is an important treatment option for patients suffering from estrogen receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer (ABC) who have been previously treated with a nonsteroidal aromatase inhibitor (NSAI). After presentation of phase III registration trial BOLERO-2, several phase IIIb trials have been started to evaluate this regimen in a more real-world setting. Here, we review the efficacy and safety data published or presented at selected international meetings. These studies confirmed the ­outcome observed in the BOLERO-2 trial. Patient acceptance rate is also discussed by focusing on the permanent everolimus discontinuation rate in these trials. Factors influencing the safety profile are also reported, including the impact of age. The optimal sequence of combined therapy approaches associating targeted and endocrine therapy (ET) has yet to be determined as new treatment options such as cyclin-dependent kinase inhibitors become available. However, everolimus–exemestane remains an important treatment option with a major impact on progression-free survival (PFS) and an acceptable safety profile.



Downloads

PDF  (1.19 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)





Quick Links


New article and journal news notification services